Category - Developments

Developments

Bee Vectoring in cranberry trials with natural pesticide

Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) plans to conduct trials of its natural precision agriculture system on cranberries in Massachusetts and New Jersey, two major cranberry growing...

May 20, 2020

Developments

Maxim ups Co-Diagnostics to buy; PT $30

Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...

May 20, 2020

Developments

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...

May 19, 2020

Developments

HalioDx to generate tumor immune contexture data for ImCheck Phase 1/2 trial

HalioDx, a closely-held immuno-oncology diagnostic company, signed a collaboration with ImCheck Therapeutics to generate tumor immune contexture information for patients enrolled in EVICTION, the first-in-human clinical...

May 19, 2020

Developments

Kane Biotech recommences trading on the OTCQB

Kane Biotech’s (TSX-V:KNE) shares will recommence trading on the OTCQB Venture Market on May 19, 2020. Kane Biotech’s shares have been trading under the Pink Open Market since Feb. 4, 2019. With the upgrade to the...

May 19, 2020

Developments

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) is planning to commence a Phase 2a trial of CRV431 for the treatment of NASH fibrosis in June. The study, called AMBITION, will enroll 18 adults with presumed NASH F2- or F3-stage...

May 19, 2020

Developments

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Cassava Sciences (NASDAQ:SAVA) reported disappointing topline results from its Phase 2b study of PTI-125 for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85...

May 15, 2020

Developments

Capricor reports positive topline data from Phase 2 DMD trial

Capricor Therapeutics (NASDAQ:CAPR) reported positive topline 12-month results of its Phase 2 clinical trial of CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002-treated patients demonstrated...

May 13, 2020

Developments

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

AVROBIO (NASDAQ:AVRO) updated data on its Phase 2 and Phase 1/2 trials evaluating its lentiviral-based gene therapies for the treatment of Fabry disease and cystinosis, respectively. Fabry disease is a genetic disease...

May 13, 2020

Developments

Gamida Cell reports positive topline data from Phase 3 omidubicel trial

Gamida Cell (NASDAQ:GMDA) reported positive topline results from its Phase 3 study of omidubicel in patients with high-risk hematologic malignancies undergoing a bone marrow transplant. The study achieved its primary...

May 12, 2020

Category - Developments

Bee Vectoring in cranberry trials with natural pesticide

Maxim ups Co-Diagnostics to buy; PT $30

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

HalioDx to generate tumor immune contexture data for ImCheck Phase 1/2 trial

Kane Biotech recommences trading on the OTCQB

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Cassava Sciences PTI-125 fails Phase 2b Alzheimer’s disease study

Capricor reports positive topline data from Phase 2 DMD trial

AVROBIO updates data on gene therapy trials for Fabry disease, cystinosis

Gamida Cell reports positive topline data from Phase 3 omidubicel trial

General

More